Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN).

Trial Profile

Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN).

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Oct 2012 Results were reported in a Inovio media release, and were published in Science-Translational Medicine.
    • 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (Extension trial: NCT01188850)
    • 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (Extension trial: NCT01188850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top